The correlations between EMT cell state, intermediary metabolic output, and Nrf2 activity are significant in both Nrf2 knockout mouse model and in human NSCLC adenocarcinomas, with implications for the use of Nrf2/redox modulators in cancer therapy. This evidence concerns the gene NFE2L2 and cancer.